The main objective of the present study was to develop formulations of noscapine hydrochloride hydrate with enhanced solubility and bioavailability using co-solvent- and cyclodextrin-based approaches.
Tablet formulation of an active pharmaceutical ingredient with a sticking and filming problem: direct compression and dry granulation evaluations
Direct compression and dry granulation tableting techniques were evaluated using factorial experimental design.
Permeability Enhancing Lipid-Based Co-Solvent and SEDDS Formulations of SQ641, an Antimycobacterial Agent
Abstract Context: Tuberculosis (TB) is a common and often deadly infectious disease caused by strains of Mycobacteria. Development of new anti-tubercular drugs is essential to control the emergence and severity of multidrug-resistant TB. Objective: The objective of this study was to develop an oral preclinical liquid formulation of SQ641 and to determine the permeability across rat intestinal tissue by Ussing chamber. Methods: Thermal and chemical characterization of SQ641 was performed by differential scanning calorimetric analysis, thermogravimetric analysis and high performance liquid chromatography. A high throughput solubility screening technique was utilized to determine the solubility of SQ641 in different solvents and co-solvents. Several co-solvent and self-emulsifying drug delivery system (SEDDS) formulations were selected for Ussing chamber permeability studies. Results and discussion: Calculated average apparent permeability coefficients of SEDDS formulations of SQ641 (ranging from 0.03 × 10-6 to 0.33 × 10-6) were found to be higher than the permeability coefficients of co-solvent formulations (ranging from 0.00 × 10-6 to 0.09 × 10-6) and those of the neat drug SQ641 in buffer (0.00 × 10-6). Conclusion: SEDDS formulations with superior permeability characteristics may provide a useful dosage form for oral intake of anti-tubercular drug SQ641, possibly due to the increase in solubility and immediate dispersion of drug.
Development of Powder-in-Bottle Formulation of Hydroxyurea with Methylparaben Preservative
The compatibility of hydroxyurea with excipients in closed cap conditions at 30°C/65%RH and 40°C/75%RH storage for up to 6 weeks was also studied.